D-0844-2020 Class III Terminated
FDA drug recall D-0844-2020 was initiated by The Harvard Drug Group on Dec 13, 2019 and is designated Class III. Reason for recall: Failed Dissolution Specifications: High out of specification result observed at stability studies. The recall status is terminated (terminated Nov 4, 2020). Affected quantity: 246 Cartons.
Recall details
- Product Type
- Drugs
- Report Date
- Feb 26, 2020
- Initiation Date
- Dec 13, 2019
- Termination Date
- Nov 4, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 246 Cartons
Product description
Memantine Hydrochloride Extended-release Capsules, 28mg, packaged in 100-count Unit Dose Cartons , Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202 United States; Distributed by: Major Pharmaceuticals, 17177 N Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6735-61
Reason for recall
Failed Dissolution Specifications: High out of specification result observed at stability studies.
Distribution pattern
U.S.A. Nationwide
Code information
Lot# M02465D
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0844-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026